These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 31960060)
41. Eosinophil sequestration and activation are associated with the onset and severity of systemic adverse reactions following the treatment of onchocerciasis with ivermectin. Cooper PJ; Awadzi K; Ottesen EA; Remick D; Nutman TB J Infect Dis; 1999 Mar; 179(3):738-42. PubMed ID: 9952390 [TBL] [Abstract][Full Text] [Related]
42. Mass treatment of onchocerciasis with ivermectin: should people with epilepsy and/or growth-retardation syndromes be excluded? Twum-Danso NA Ann Trop Med Parasitol; 2004 Mar; 98(2):99-114. PubMed ID: 15035720 [TBL] [Abstract][Full Text] [Related]
43. Treatment of onchocerciasis. The ocular effects of ivermectin and diethylcarbamazine. Taylor HR; Murphy RP; Newland HS; White AT; D'Anna SA; Keyvan-Larijani E; Aziz MA; Cupp EW; Greene BM Arch Ophthalmol; 1986 Jun; 104(6):863-70. PubMed ID: 3521559 [TBL] [Abstract][Full Text] [Related]
44. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Horton J; Witt C; Ottesen EA; Lazdins JK; Addiss DG; Awadzi K; Beach MJ; Belizario VY; Dunyo SK; Espinel M; Gyapong JO; Hossain M; Ismail MM; Jayakody RL; Lammie PJ; Makunde W; Richard-Lenoble D; Selve B; Shenoy RK; Simonsen PE; Wamae CN; Weerasooriya MV Parasitology; 2000; 121 Suppl():S147-60. PubMed ID: 11386686 [TBL] [Abstract][Full Text] [Related]
45. Population pharmacokinetics of ivermectin for the treatment of scabies in Indigenous Australian children. Gwee A; Duffull S; Zhu X; Tong SYC; Cranswick N; McWhinney B; Ungerer J; Francis J; Steer AC PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008886. PubMed ID: 33284799 [TBL] [Abstract][Full Text] [Related]
46. Ivermectin-induced fixed drug eruption in an elderly Cameroonian: a case report. Ngwasiri CA; Abanda MH; Aminde LN J Med Case Rep; 2018 Sep; 12(1):254. PubMed ID: 30201032 [TBL] [Abstract][Full Text] [Related]
48. Ivermectin: new indication. Oral treatment of scabies: simple and effective. Prescrire Int; 2002 Oct; 11(61):137-40. PubMed ID: 12378743 [TBL] [Abstract][Full Text] [Related]
49. Treatment of 18 children with scabies or cutaneous larva migrans using ivermectin. del Mar Sáez-De-Ocariz M; McKinster CD; Orozco-Covarrubias L; Tamayo-Sánchez L; Ruiz-Maldonado R Clin Exp Dermatol; 2002 Jun; 27(4):264-7. PubMed ID: 12139665 [TBL] [Abstract][Full Text] [Related]
50. Adverse events following mass ivermectin therapy for onchocerciasis. Chijioke CP; Okonkwo PO Trans R Soc Trop Med Hyg; 1992; 86(3):284-6. PubMed ID: 1412654 [TBL] [Abstract][Full Text] [Related]
51. Maintaining compliance to ivermectin in communities in two West African countries. Whitworth JA; Alexander ND; Seed P; Thomas W; Abiose A; Jones BR Health Policy Plan; 1996 Sep; 11(3):299-307. PubMed ID: 10160375 [TBL] [Abstract][Full Text] [Related]
52. Efficacy and Safety of Ivermectin Against Trichuris trichiura in Preschool-aged and School-aged Children: A Randomized Controlled Dose-finding Trial. Wimmersberger D; Coulibaly JT; Schulz JD; Puchkow M; Huwyler J; N'Gbesso Y; Hattendorf J; Keiser J Clin Infect Dis; 2018 Sep; 67(8):1247-1255. PubMed ID: 29617737 [TBL] [Abstract][Full Text] [Related]
53. Moxidectin: an oral treatment for human onchocerciasis. Milton P; Hamley JID; Walker M; Basáñez MG Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1067-1081. PubMed ID: 32715787 [TBL] [Abstract][Full Text] [Related]
54. Ivermectin for the chemotherapy of bancroftian filariasis: a meta-analysis of the effect of single treatment. Cao WC; Van der Ploeg CP; Plaisier AP; van der Sluijs IJ; Habbema JD Trop Med Int Health; 1997 Apr; 2(4):393-403. PubMed ID: 9171850 [TBL] [Abstract][Full Text] [Related]
55. Ivermectin: effectiveness in lymphatic filariasis. Brown KR; Ricci FM; Ottesen EA Parasitology; 2000; 121 Suppl():S133-46. PubMed ID: 11386685 [TBL] [Abstract][Full Text] [Related]
56. Evaluating the Risks of Systemic Maternal Ivermectin Exposure During Pregnancy in Human and Vertebrate Animals: A Scoping Review. Westlake CS; Aronoff DM Curr Drug Saf; 2021; 16(3):299-308. PubMed ID: 33109066 [TBL] [Abstract][Full Text] [Related]
57. Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials. De Sole G; Remme J; Awadzi K; Accorsi S; Alley ES; Ba O; Dadzie KY; Giese J; Karam M; Keita FM Bull World Health Organ; 1989; 67(6):707-19. PubMed ID: 2633886 [TBL] [Abstract][Full Text] [Related]
58. The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients. Awadzi K; Attah SK; Addy ET; Opoku NO; Quartey BT Trans R Soc Trop Med Hyg; 1999; 93(2):189-94. PubMed ID: 10450448 [TBL] [Abstract][Full Text] [Related]
59. Individuals living in an onchocerciasis focus and treated three-monthly with ivermectin develop fewer new onchocercal nodules than individuals treated annually. Campillo JT; Chesnais CB; Pion SDS; Gardon J; Kamgno J; Boussinesq M Parasit Vectors; 2020 May; 13(1):258. PubMed ID: 32414398 [TBL] [Abstract][Full Text] [Related]